Skip to main content
Contact Us
Subscribe
E-Edition
60°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Renalytix Ai Plc ADR
(NQ:
RNLX
)
0.6358
-0.0637 (-9.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Renalytix Ai Plc ADR
< Previous
1
2
Next >
Renalytix Announces Financing with Expected Size of up to $4 Million
April 08, 2024
From
Renalytix plc
Via
GlobeNewswire
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
March 14, 2024
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk
From
Renalytix plc
Via
GlobeNewswire
Renalytix PLC (NASDAQ: RNLX) Near the Top of Equities by Percentage Gain on 6/30
June 30, 2023
Via
Investor Brand Network
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
February 15, 2024
From
Renalytix plc
Via
GlobeNewswire
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 09, 2024
From
Renalytix plc
Via
GlobeNewswire
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
January 10, 2024
From
Renalytix plc
Via
GlobeNewswire
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
November 14, 2023
From
Renalytix plc
Via
GlobeNewswire
Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14
November 07, 2023
From
Renalytix plc
Via
GlobeNewswire
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix
October 06, 2023
From
Renalytix plc
Via
GlobeNewswire
Renalytix Reports Full Year Fiscal 2023 Results
September 28, 2023
From
Renalytix plc
Via
GlobeNewswire
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28
September 25, 2023
From
Renalytix plc
Via
GlobeNewswire
Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer
September 07, 2023
Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort
From
Renalytix plc
Via
GlobeNewswire
Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd
August 03, 2023
World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease
From
Renalytix plc
Via
GlobeNewswire
Renalytix Announces Middle East Distribution Agreement with Vector Pharma
July 21, 2023
From
Renalytix plc
Via
GlobeNewswire
Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions
July 07, 2023
From
Renalytix plc
Via
GlobeNewswire
Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors
July 03, 2023
From
Renalytix plc
Via
GlobeNewswire
FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease
June 29, 2023
From
Renalytix plc
Via
GlobeNewswire
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
June 09, 2023
From
Renalytix plc
Via
GlobeNewswire
Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9
June 05, 2023
From
Renalytix plc
Via
GlobeNewswire
Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes
May 25, 2023
Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage
From
Renalytix plc
Via
GlobeNewswire
New Published Real-World Evidence Shows KidneyIntelX™ Utility
April 19, 2023
From
Renalytix plc
Via
GlobeNewswire
Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting
April 12, 2023
From
Renalytix plc
Via
GlobeNewswire
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
March 30, 2023
From
Renalytix plc
Via
GlobeNewswire
Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30
March 22, 2023
From
Renalytix plc
Via
GlobeNewswire
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 09, 2023
From
Renalytix plc
Via
GlobeNewswire
Renalytix announces a c.$20.3 million private placement
February 08, 2023
From
Renalytix plc
Via
GlobeNewswire
Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States
January 26, 2023
Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney disease
From
Renalytix plc
Via
GlobeNewswire
Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systems
January 09, 2023
Significant milestone will make KidneyIntelX accessible to 960,000 veterans with chronic kidney disease
From
Renalytix AI, Inc.
Via
GlobeNewswire
Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes
December 01, 2022
First-in-class bioprognostic™ KidneyIntelX provided clear direction for primary care physicians to slow or stop progression of chronic kidney disease in adult diabetes patients
From
Renalytix AI, Inc.
Via
GlobeNewswire
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023
November 30, 2022
From
Renalytix AI, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.